The Development of China′s Regulatory Policy for Segmented Production of Biological Products
and the Pilot Explorationin Guangdong Province

doi:magtech.2025.06.17-00001

Abstract

Abstract:

Under the background of rapid development in the biomedical industry and strong support from national policies， the segmented production model for biological products in China has gradually emerged as a critical pathway to overcome industry bottlenecks and optimize resource allocation. This study systematically reviews the evolution of China's regulatory policies for the segmented production of biological products， elucidating the logic of the institutional transition from "prohibiting contract manufacturing" to "pilot exploration." However， risks such as cross-regional coordination， responsibility tracing， and cold chain logistics continue to constrain industry development. Guangdong province， through proactive services， facilitated the segmented production pilot project for pharmaceutical enterprises in the province， significantly expediting drug registration， approval， and the commencement of commercial production. This study analyze， the background of segmented production for biological products and the risks and challenges encountered during the implementation of its regulatory policies， reviews the development process of China's regulatory policies on the segmented production of biological products， summarize， the pilot implementation and outcomes in Guangdong province. Furthermore， it proposes recommendations focusing on three key aspects： the quality management system， product technology，and communication and coordination.Additionally， based on current regulatory practices， the study offers insights on key issues related to digital applications， tiered supervison， dynamic risk control， and cross-border collaboration so as to provide valuable experience for the comprehensive nationwide promotion of this model.

Key words: , Biologics； , Segmented production； , Regulatory policies； , Pilot exploration

CLC Number:

XIE Yankang, WEI Xiaomei, YANG Yunhan, ZOU Yuting.

The Development of China′s Regulatory Policy for Segmented Production of Biological Products and the Pilot Explorationin Guangdong Province [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(11): 1133-1133-1137.

References

［1］沈竹林，刘力，王小理.如何进一步促进生物医药产业发展［N］.学习时报，2023-08-28.

［2］国务院.中华人民共和国药品管理法［EB/OL］.（2019-08-26）［2025-03-19］.https：//www.gov.cn/xinwen/2019-08/26/content_5424780.htm.

［3］顾瑶华，操桂兰，董锐，等.我国生物制品分段生产可行性建议——基于苏州工业园区生物医药产业的探索［J］.中国食品药品监管，2021，（12）：112-117.

［4］ U.S.FDA.Approval Package for Application Number：125514Orig1s000［EB/OL］.（2014-09-04）［2025-03-19］.https：//www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000Approv.pdf.

［5］原国家食品药品监督管理总局.国家食品药品监督管理总局关于发布药品委托生产监督管理规定的公告（2014年第36号）［EB/OL］.（2014-08-14）［2025-03-19］.https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20140814110901422.html.

［6］国务院.中华人民共和国疫苗管理法［EB/OL］.（2019-06-30）［2025-03-19］.https：//www.gov.cn/xinwen/2019-06/30/content_5404540.htm.

［7］国家药品监督管理局.国家药监局关于发布《疫苗生产流通管理规定》的公告（2022年第55号）［EB/0L］.（2022-07-08）［2025-03-19］.https：//www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20220708185734126.html.

［8］国家药品监督管理局.国家药监局关于印发生物制品分段生产试点工作方案的通知（国药监药管〔2024〕24号）［EB/OL］.（2024-10-22）［2025-03-19］.https：//www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20241022112249149.html.

［9］国家药品监督管理局食品药品审核查验中心.国家药监局食品药品审核查验中心关于发布《生物制品分段生产现场检查指南》的通告［EB/OL］.（2024-11-01）［2025-03-19］.https：//www.cfdi.org.cn/cfdi/resource/news/16139.html.

［10］国家药品监督管理局药审中心.国家药监局药审中心关于发布《抗体偶联药物分段生产试点注册申报技术要求》的通告（2024年第47号）［EB/OL］.（2024-11-07）［2025-03-19］.https：//www.cde.org.cn/main/news/viewInfoCommon/612aa2c85a18c269b8d352202865b71e.

［11］国务院.国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见（国办发〔2024〕53号）［EB/OL］.（2025-01-03）［2025-03-19］.https：//www.gov.cn/zhengce/content/202501/content_6996115.htm.

［12］广东省政府.广东省政府办公厅关于进一步推动广东生物医药产业高质量发展行动方案的通知（粤府办〔2024〕11号）［EB/OL］.（2024-10-08）［2025-03-19］.http：//www.gd.gov.cn/zwgk/wjk/qbwj/yfb/content/post_4504697.html.

［13］广东省药监局.重大突破！广东第一批生物制品分段生产试点品种出炉！［EB/OL］.（2025-01-02）［2025-03-19］.https：//mp.weixin.qq.com/s/8CwHWJno2rc4yTuKZ4nmYg.

［14］韩雨，颜若曦.生物制品分段生产质量管理要点探讨［J］.中国药物评价，2025，42（2）：86-90.

［15］国家药品监督管理局.国家药监局关于发布药品委托生产质量协议指南（2020年版）的公告（2020年第107号）［EB/OL］.（2020-09-27）［2025-03-19］.https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20201009174033199.html.

［16］曹萌，成殷，王佳静，等.生物制品分段委托生产情形下的持有人质量管理体系关注点探讨［J］.中国医药工业杂志，2025，56（4）：552-558.

[1]	WANG Caixue, SUN Ting, LI Xuan, SHAN Bin, WEN Tianjiao, WANG Mingxia. Analysis of Development Status and Challenges of Drug Clinical Trial Tnstitution in Hebei Province [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 995-1000.
[2]	JIAO Jian, XU Liang, YANG Lingyan. The Construction of A “Dual-Practice” Training Model for Inter-Disciplinary TCM Management Talents in Hospitals under the Background of "New Medicine" [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 967-973.
[3]	CAO Jie, TIAN Neng, WANG Huan. The Application of Cupping Therapy in Common Pediatric Diseases [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 902-906.
[4]	WANG Xiaolan, XIE Guifang, JIANG Yan, Zhang Xiaoqian, REN Kun. Study on Migration of Styrene from Disposable Intravenous Indwelling Needle in 5 Kinds of Liquid Medicine [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 954-959.
[5]	ZHU Xiaoyue, ZHANG Zhe, SUN Yi, AN Jingye, ZHENG Jie, WU Zhaowei. Improvement of Determination Method about Vitamin D₃ Assay in Standards for Calcium Carbonate and Vitamin D₃ Preparations [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 950-953.
[6]	KONG Weisong, CAO Dengyan, SHI Xuemin, XUE Ya, JIA Tingting, QIAN Fengdan, XU Yanfeng, ZHANG Lichao. Comparative Analysis of Requirements on Medical Institutions from Management Rules for Traditional Chinese Medicine Formula Granules among Provinces [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 960-966.
[7]	XIE Qing, GUO Qing, MIAO Lili. Relationship between the Risk of MACE during the Vulnerable Phase and Relevant Test Indexes in Patients with Acute Heart Failure [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 907-911.
[8]	LI Jihong, CHEN Jing, NIAN Honglei, WANG Xinghe. Exploration of the Full Chain Protection Strategy for the Rights and Interests of Participants in Clinical Research of Cell Therapy [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 987-994.
[9]	YIN Yanli, XU Renen. Application and Thinking of Remote Monitoring in Drug Regulation [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 878-881.
[10]	ZUO Yangbin, LI Jin, LIN Tianyu, WU Lijuan, CHEN Chunxi. Epidemiological Characteristics of Multi-Drug Resistant Mycobacterium Tuberculosis and Analysis of Factors Affecting Patient Treatment Adherence [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 982-986.
[11]	CHEN Wenping, WANG Guangping, ZHANG Ji. Hospital Pharmacovigilance System Based on Management Model of External Prescription Dispensing [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 882-888.
[12]	BIAN Xiaoyue, LIANG Yaxing, YIN Chen, YANG Xueying, WANG Hongying, ZHAO Yurong. Research Progress on 3D Printing Materials and 3D Printing Technology for Cranioplasty [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 889-895.
[13]	FU Jiyou, SHANG Qinghui, JIANG Lin, MAO Xiao, LI Yang. Research Progress on the Efficacy， Indications， Clinical Applications， and Modern Pharmacological Effects of Baibu [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 896-901.
[14]	LIU Chunyu, YANG Wanjun, WEI Namin, ZHANGnan , ZHAI Huaqiang, JIN Shiyuan. Bibliometrics Research on Traditional Chinese Medicine in the Treatment of Lung Cancer in Recent 10 Years [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 930-939.
[15]	LIU Zhihui, LU Meijing, YIN Li, YANG Yuanyuan, WANG Jiaxin, WANG Shigong. Study on the Characteristics and Meteorological Triggers of Circulatory System Diseases in Panzhihua Based on Machine Learning [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(9): 974-981.

The Development of China′s Regulatory Policy for Segmented Production of Biological Products and the Pilot Explorationin Guangdong Province

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments